CytRx (NASDAQ:CYTR) said that additional preliminary data from its Phase 2b clinical trial, demonstrating aldoxorubicin’s potential advantage over doxorubicin in the treatment of soft tissue sarcoma (STS), will be presented at the Annual Connective Tissue Oncology Society (CTOS) meeting on Oct. 31 at 4:30 p.m. ET at the Sheraton New York Times Square Hotel.
The company previously reported that patients in the trial treated with aldoxorubicin had an overall response rate (ORR) of 22%, while those administered the widely used chemotherapeutic agent, doxorubicin, had an ORR of 0%. CytRx expects to report top-line data for the Phase 2b clinical trial in December 2013.
In a statement, president and CEO Steven Kriegsman said CTOS provides an ideal forum to gain awareness of this compelling data and to acquaint oncologists with the company’s Phase 3 study in patients with relapsed or refractory soft tissue sarcomas.
“Discoveries of new sarcoma treatments have been relatively few, particularly when compared with treatments for breast or prostate cancer, but the preliminary clinical results thus far drive our optimism that aldoxorubicin can fill an important medical need in patients with advanced soft tissue sarcoma,” he added.
In addition to the Phase 2b trial for STS, the FDA has cleared the company for a protocol to conduct a Phase 2 clinical trial with aldoxorubicin in glioblastoma. It also plans to conduct a Phase 2 clinical trial in HIV-related Kaposis sarcoma.
